https://www.law360.com/healthcare-authority/deals-corporate-governance/articles/2322119/incyte-can-t-get-pretrial-win-in-novartis-royalty-fight
A little insight into what a treatment for MF is worth to big Pharma.
Incyte and Novartis heading into a jury trial over royalties for ruxolitinib.
Both Pharma using 2 separate law firms and over 10 lawyers. I would suggest they don't come cheap
Novartis is represented by Robert C. Mike Brock, Donna M. Welch, Michael F. LeFevour, Alexandra Schrader, Danielle O'Neal and Jeremy Roux of Kirkland & Ellis LLP and Hal S. Shaftel, Sylvia E. Simson, John C. Molluzzo Jr., Michael E. Mirdamadi and Andrea Chidyllo of Greenberg Traurig LLP.
Incyte is represented by F. Dominic Cerrito, Eric Stops, Ellyde R. Thompson, Andrew S. Chalson, Luke H. Phillips, William Price and Michael Lifrak of Quinn Emanuel Urquhart & Sullivan LLP and Eric W. Dittmann, Joshua M. Bennett, Avi Weitzman and Melanie R. Rupert of Paul Hastings LLP.
Add to My Watchlist
What is My Watchlist?
